Agenus (NASDAQ:AGEN) Stock Rating Lowered by Wall Street Zen

Agenus (NASDAQ:AGEN) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agenus currently has a consensus rating of “Hold” and an average price target of $14.50.

Agenus Stock Performance

Shares of AGEN opened at $3.24 on Friday. The firm has a market cap of $124.42 million, a PE ratio of -7.04 and a beta of 1.56. The firm’s 50 day moving average price is $3.20 and its 200 day moving average price is $3.71. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, topping the consensus estimate of ($1.27) by $1.83. The company had revenue of $34.20 million during the quarter, compared to the consensus estimate of $28.10 million. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. On average, sell-side analysts anticipate that Agenus will post -12.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC acquired a new stake in shares of Agenus in the fourth quarter worth $31,000. R Squared Ltd bought a new stake in shares of Agenus during the 4th quarter worth $41,000. Redwood Family Wealth LLC acquired a new position in Agenus in the 4th quarter valued at $44,000. Traynor Capital Management Inc. acquired a new position in Agenus in the 3rd quarter valued at $50,000. Finally, Quadrature Capital Ltd bought a new position in Agenus in the 4th quarter worth $54,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.